Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06127160 · ClinicalTrials.gov registry record · Phase 4
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
A Phase 4 study, sponsored by Brett A Faine.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT06127160 is a Phase 4 study that has completed, run by Brett A Faine. The registered enrollment target is 35 participants.
The verdict
NCT06127160, a Phase 4 study, has completed, sponsored by Brett A Faine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale multi-center randomized controlled trial.
Interventions
- DRUG Cephalexin
- DRUG Cephalexin or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06127160
The ClinicalTrials.gov registry entry for NCT06127160 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brett A Faine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cephalexin is the first listed.
NCT06127160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06127160 about?
NCT06127160 is a clinical study titled "Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis". This pilot study will randomize 40 female patients with acute uncomplicated pyelonephritis to receive standard duration of therapy versus patient-directed antimicrobial duration (PDAD). The primary objectives of this pilot trial are to determine the feasibility and safety of conducting a full-scale ...
What is the current status of trial NCT06127160?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2024-06-04. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT06127160?
The interventions under investigation include: Cephalexin (DRUG), Cephalexin or placebo (DRUG).
Who is sponsoring clinical trial NCT06127160?
This trial is sponsored by Brett A Faine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.